argenx SE
SWB:1AE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
argenx SE
SWB:1AE
|
NL |
|
Arkema SA
PAR:AKE
|
FR |
|
MetalQuest Mining Inc
F:E7Q
|
CA |
|
H
|
Hexatronic Group AB
XMUN:02H0
|
SE |
|
R
|
Ratchaphruek Hospital PCL
SET:RPH
|
TH |
|
P
|
Palantir Technologies Inc
F:PTX
|
US |
|
Bonduelle SA
F:BDU
|
FR |
|
M
|
Molson Coors Beverage Co
F:NY7
|
US |
|
Sabra Health Care REIT Inc
F:SBC
|
US |
|
N
|
Nomura Research Institute Ltd
XMUN:NR7
|
JP |
|
I
|
Integrated Drilling Equipment Holdings Corp
OTC:IRIG
|
US |
|
First Mining Gold Corp
TSX:FF
|
CA |
|
A
|
Alla PCL
SET:ALLA
|
TH |
|
H
|
Hormel Foods Corp
F:HO7
|
US |
Intrinsic Value
Is 1AE undervalued or overvalued?
See the intrinsic value estimate for 
argenx SE and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What argenx Does
argenx is a biotechnology company that develops antibody-based medicines for serious autoimmune diseases, where the body attacks its own tissues. Its best-known product is VYVGART, a prescription therapy used by specialist doctors and hospitals to treat certain immune disorders. The company also has a pipeline of follow-on drug candidates built around the same antibody engineering platform.
- Headquarters
- Netherlands NL
- Employees
- 1 863
- IPO date
- Jul 10, 2014
argenx has a narrow economic moat
Patents covering Vyvgart’s active medicine and its uses prevent rivals from freely copying argenx’s main treatment. This protects its profits without shutting out competing medicines such as UCB’s Rystiggo and Johnson & Johnson’s Imaavy.
Read the full moat analysis
Earnings Waterfall
argenx SE
The intrinsic value for argenx SE (1AE) under the Base Case is hidden EUR.
Compared with the current market price of 797.8 EUR, the stock appears hidden.